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A B S T R A C T
Articles reporting the diagnostic accuracy of non-invasive prenatal diagnostic (NIPD) tests for RHD
genotyping using fetal material extracted from maternal blood have been published steadily for over a
decade. Health care providers in Europe have started to use this technology for management of the small
number of sensitised pregnancies (ca. 220–600 per annum in the Netherlands, Germany, France and the
UK). Scientists and clinicians are also advocatingwidespread implementation for the far larger number of
non-sensitised RhD-negative pregnancies (ca. 34,000–125,000 per annum in the same countries). Large-
scale, prospective trials are only now underway. Estimates of the technical performance of these tests are
currently based on results from small-scale studies, together with formal meta-analysis. The issue of
early assessment of test performance is one faced by many new genetic tests. As part of a wider study we
have investigated the quality of reporting of diagnostic accuracy in publications and produced guidelines
for future studies.
A systematic search of the literature identiﬁed 27 paperswhichmet predeﬁned inclusion criteria. All
27 papers were, ﬁrst, assessed against an international quality (STARD) checklist for reporting of
diagnostic accuracy and, second, against our own in-house NIPD proforma to assess the implications of
the quality of reporting speciﬁcally for the RhD NIPD test. Authors were found to generally present an
optimistic viewofNIPD, bearing inmindweaknesses identiﬁed in reporting and conduct of their studies
and the analysis of results, as evidenced by the low STARD scores. The NIPD proforma identiﬁed that
speciﬁc biases were potentially introduced through selective population sampling and/or failure to
report the make-up of the population tested, omission of inconclusive results, inconsistencies in the
handling of repeat results on a sample, and lack of adequate controls. These factors would inevitably
affect the validity of diagnostic accuracy as reported in individual publications, as well as any
subsequent meta-analyses. Together, published reports to date may provide a biased picture of the
actual potential of NIPD testing for fetal RHD genotyping. Generalisation of the available evidence on
diagnostic accuracy, especially to large-scale implementation ofNIPD testing of non-sensitisedwomen,
will also require that decisionmakers consider further aspects such as test reliability and cost of routine
testing in clinical practice.
It is recommended that all studies of diagnostic accuracy of NIPD tests adhere to the STARD
quality checklist in order to improve reporting, thereby, minimising bias and increasing the
comparability of studies. Researchers should also consider speciﬁc shortcomings for NIPD and avoid
selective participant sampling; report population characteristics; report handling of replicate
sampling as well as their failure rates; and include controls for genotypes tested in the study.
Furthermore, meta-analyses should consider the quality, as well as the sample size, of NIPD studies
in their analysis. Larger trials, required to produce results that are valid and meaningful for clinical
practice, must also adhere to these reporting standards.
 2008 Published by Elsevier Ireland Ltd.
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Fetal RHD genotyping from maternal whole blood [1], fetal
cells [2] or cell free fetal DNA [3] in maternal blood has been
feasible for over a decade. Following the ﬁrst papers, research
interest in this formof non-invasive prenatal diagnosis (NIPD) has
become global. Publications in Europe, America and Australia aim
to improve the management of pregnancies of women who are
rhesus negative [2,4–9]. In white Caucasian populations about
10% of all pregnancies involve an RhD-negative mother and an
RhD-positive fetus, potentially placing the mother at risk of
sensitisation and future babies at risk of haemolytic disease of the
fetus and newborn (HDFN).
Anti-D immunoglobulin can be given to prevent a woman
producing antibodies against fetal RhD-positive blood cells.
Introduction of postnatal anti-D prophylaxis (within 72 h of
delivery) in the late 1960s reduced sensitisation and HDFN rates
considerably internationally. Combined with antenatal prophy-
laxis for high-risk events, such as amniocentesis, this form of
targeted prophylaxis has proved highly effective and cost-effective
[10]. Consequently, the number of sensitised RhD-negativewomen
who give birth every year is lower than 1% of total births.
For non-sensitised women, routine antenatal anti-D prophylaxis
(RAADP) at 28–30 weeks gestation was introduced in the mid-
1990s, and is now available in most European countries. However,
40% of RhD-negative women receive this blood product unnecessa-
rily because the fetus is not RhD-positive. Fetal RHD genotyping has
the potential to enable targeted antenatal prophylaxis only for
women whose pregnancy is at risk. This might address any issues
of limited anti-D supplies and perceived risk associated with
unnecessary administration of a blood product.
The NIPD RHD genotyping test has already started to have an
impact on the management of sensitised women, in countries
where this technology is available, by replacing invasive proce-
dures like amniocentesis for the determination of fetal RhD status.
Replacement of amniocentesis is desirable since the procedure can
promote feto–maternal blood exchange as well as being associated
with a small increased risk of miscarriage [11,12].
The current state of development of the RhD NIPD test is
promising. Several studies have reported high accuracy rates [13–
16] and these have prompted the initiation of larger scale trials in
the Netherlands, Germany and the UK [17–18]. Reports in the
literature have already led to initial use of the test for management
of sensitised women. An increasing focus of debate is now on
widespread implementation of the test in non-sensitised preg-
nancies [19]. Discussion of markers (exons and/or introns) to be
used for RHD genotyping, and the applicability of NIPD tests forPlease cite this article in press as: Freeman K, et al. Non-invasive fe
reporting of diagnostic accuracy in published studies. Eur J Obstet Groutine clinical use in diverse populations form part of this debate
[13,17].
A recent meta-analysis undertaken by Geifman-Holtzman et al.
has reported sensitivity and speciﬁcity values of 0.986 and 0.954
respectively, and an overall positive predictive value of 0.990 and
negative predictive value of 0.921 [20]. Some studieswere excluded
from thismeta-analysis on the basis of samplenumbers, but aspects
such as study quality were not considered. Because assessment of
the quality of reporting of diagnostic accuracy can be problematic, a
world-wideDelphi panel has identiﬁed agreed international quality
criteria for assessing the reporting of such studies [21]. The resulting
checklist (STARD -standards for reporting studies of diagnostic
accuracy) is now required from all authors of health technology
assessment reports of diagnostic technologies in the UK, and
increasingly requested by editors of international journals.We have
undertaken an independent systematic literature search and
assessed the quality of reporting of all identiﬁed articles using the
STARD checklist. We further investigated the implications of any
shortcomings on the generalisability of NIPD study results, in order
to identifykeyaspects inﬂuencing test reliabilityandanyunderlying
reporting biases. An NIPD assessment proforma has been produced
as well as recommendations that are speciﬁc and relevant for
reporting diagnostic accuracy of RhD NIPD tests.
2. Methods
2.1. Literature search strategy
Published articles were identiﬁed by systematic searches of
electronic databases from 1966 until January 2007; these included
PubMed, Ovid Medline, Ovid Embase, the Cochrane Library, the
National Library for Health (UK), Online Computer Library Center
(OCLC) and the Conference Papers Index. Text words and MeSH
headings used separately and in combination included: prenatal
diagnosis, Rh, fetal cells, fetal DNA, maternal blood, serum, plasma,
Rh alloimmunis(z)ation. Bibliographies of all papers identiﬁed
were examined. Searches for related articles by topic and author
were carried out in PubMed where possible. No restriction was set
on publication type or language.
2.2. Selection process for papers for review
All retrieved publications were read and assessed in respect of
study type, patient/sample numbers and the stated study aim/
research question. Papers not in English were translated. Studies
that contained information on the diagnostic accuracy of RhDNIPD
were identiﬁed. Short abstracts, letters and case reports weretal RHD genotyping tests: A systematic review of the quality of
ynecol (2008), doi:10.1016/j.ejogrb.2008.10.010
Table 1
Coverage of the STARD checklist items by 27 papers reporting the diagnostic accuracy of RhD NIPD.
Section and topic No. Checklist items Coveragea
(%)
Title/abstract/
keywords
1 Identify the article as a study on diagnostic accuracy (recommend MeSH heading ‘sensitivity and speciﬁcity’). 61b
Introduction 2 State the research questions or study aims, such as estimating diagnostic accuracy or comparing accuracy between tests
or across participant groups.
92c
Methods
Participants 3 Describe the study population: the inclusion and exclusion criteria, setting and locationswhere the datawere collected. 32
4 Describe participant recruitment: was recruitment based on presenting symptoms, results from previous tests, or the
fact that the participants had received the index tests or the reference standard?
78
5 Describe participant sampling: was the study population a consecutive series of participants deﬁned by selection
criteria in items 3 and 4? If not, specify how participants were further selected.
12
6 Describe data collection: was data collection planned before the index test and reference standard were performed
(prospective study) or after (retrospective study)?
34
Test method 7 Describe the reference standard and its rationale. 54
8 Describe technical speciﬁcation of material and methods involved including how andwhenmeasurements were taken,
and/or cite references for index tests and reference standard.
98
9 Describe deﬁnition and rationale for the units, cutoffs and/or categories of the results of the index test(s) and the
reference standard.
0
10 Describe the number, training and expertise of the persons executing and reading the index tests and the reference
standard.
4
11 Describe whether or not the readers of the index tests and reference standard were blind (masked) to the results of the
other test and describe any other clinical information available to the readers.
28
Statistical
methods
12 Describe methods for calculating or comparing measures of diagnostic accuracy, and the statistical methods used to
quantify uncertainty (e.g. 95% conﬁdence intervals).
8
13 Describe methods for calculating test reproducibility, if done. 0
Results
Participants 14 Report when study was done, including beginning and ending dates of recruitment. 8
15 Report clinical and demographic characteristics of the study population (e.g. age, sex, spectrum of presenting
symptoms, comorbidity, current treatments and recruitment centers).
68
16 Report the number of participants satisfying the criteria for inclusion that did or did not undergo the index tests and/or
the reference standard; describe why participants failed to receive either test (a ﬂow diagram is strongly
recommended).
16
Test results 17 Report time interval from the index tests to the reference standard, and any treatment administered between. 48
18 Report distribution of severity of disease (deﬁne criteria) in those with the target condition; other diagnoses in
participants without the target condition.
0
19 Report a cross tabulation of the results of the index tests (including indeterminate andmissing results) by the results of
the reference standard; for continuous results, the distribution of the test results by the results of the reference
standard.
88
20 Report any adverse events of index tests and reference standard. 4
21 Report estimates of diagnostic accuracy and measures of statistical certainty (e.g. 95% conﬁdence intervals). 12
22 Report how indeterminate results, missing responses and outliers of index tests were handled. 62
23 Report estimates of variability of diagnostic accuracy between subgroups of participants, readers or centers, if done. 0
24 Report estimates of test reproducibility, if done. 0
Discussion
Discussion 25 Discuss the clinical applicability of the study ﬁndings. 98
a Coverage is a measure of how well the studies have adhered to items of STARD checklist (coverage =
P
(scores)/total papers), where studies covering checklist item well
score 1 point, partially 1/2 point and no coverage 0 points).
b Phrases used to identify studies as diagnostic papers included: accuracy/detection rate, sensitivity and speciﬁcity, evaluation of test reliability, efﬁciency and feasibility.
c Studies scored as long as they mentioned: evaluation or determination of test accuracy, evaluation of test reliability, efﬁciency and feasibility of test.
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fewer than 10 samples were excluded. Phrases used to identify
studies as diagnostic accuracy papers included: accuracy/detection
rate; sensitivity and speciﬁcity; evaluation of test reliability;
efﬁciency and feasibility.
2.3. Data extraction and quality assessment
A spreadsheet was prepared to extract information from the
articles ﬁnally selected. This included: year and country of
publication; number of patients/samples; source and type of
fetal material; number of replicates and exons tested; number
of positive replicates required for a result to be categorised as
positive; test failure/inconclusive result rates; accuracymeasures
reported.
Papers were then scored against the STARD checklist of 25
items, resulting in a score out of 25 for each paper whichPlease cite this article in press as: Freeman K, et al. Non-invasive fe
reporting of diagnostic accuracy in published studies. Eur J Obstet Gcorresponded to the paper’s quality as a study reporting diagnostic
accuracy. Coverage of the 25 STARD items by the 27 studies was
also reported (Table 1).
An in-house proforma was developed by collating the eight
main points of the data extraction form and categorising these
under the key elements of design deﬁciencies [22]. Papers were
also assessed against this.
3. Results
The literature search resulted in the identiﬁcation of 51
publications. The selection procedure described above excluded
24 papers (Fig. 1) leaving 27 studies for ﬁnal quality assessment
(Table 2). Of these, 25 were in English, 1 in French and 1 in Polish.
Publication dates ranged from 1996 to the end of 2006. Findings
were published in a wide range of journals and originated from 15
countries.tal RHD genotyping tests: A systematic review of the quality of
ynecol (2008), doi:10.1016/j.ejogrb.2008.10.010
Fig. 1. Flow chart describing the selection process of identiﬁed literature with reasons for exclusion.
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All studies were assigned a low score based on the STARD
checklist. Scores ranged from as low as 5/25 to 13/25 points.
Studies demonstrated weaknesses in particular elements of the
STARD checklist, as shown in Table 1. Quality of reporting was not
related to publication date or country of study. The great majority
of authors identiﬁed their paper as a report on diagnostic accuracy
(STARD item No. 1) and nearly all authors stated their aim to be
assessment of the feasibility of RhD NIPD tests (No. 2). However,Please cite this article in press as: Freeman K, et al. Non-invasive fe
reporting of diagnostic accuracy in published studies. Eur J Obstet Gfewer than one in three actually used the recommended MeSH
heading ‘sensitivity and speciﬁcity’ required for indexing papers on
diagnostic accuracy.
When reporting study methods, articles generally lacked
information on the population providing the samples, including
how participants were recruited and which women were selected,
and whether data was collected prospectively or retrospectively
(Nos. 3–6). All these will affect the comparability as well as quality
of study ﬁndings. Linked to this, the degree of blinding of test
readers (No. 11) and the statistical methods used to quantifytal RHD genotyping tests: A systematic review of the quality of
ynecol (2008), doi:10.1016/j.ejogrb.2008.10.010
Table 2
Weaknesses affecting the generalisability of reported accuracy rates of RhD NIPD in 27 studies.
Study Study population Study conduct Data analysis Study design Refs.
Selective
participant
sampling
Lack of reporting
ethnicity and/or
sensitisation status
of participants
Lack of reporting
no. of replicates
(if done) used for
overall study
outcome
Lack of
reporting
failure rate
Lack of
inclusion of
reported failure
rate into
analysis
Difference in
reported and
adjusted
accuracy
Lack of control
for presence of
fetal DNA
Lack of known
genotypes in
study as control
1 U U U [13]
2 U U U U [14]
3 U U U U U [35]
4 U U U U [15]
5 U U U U U U [26]
6 U U U U [30]
7 U U U U U [33]
8 U U U U U [28]
9 SRY only [32]
10 U U [31]
11 U U U U [16]
12 U U U U U [36]
13 U U [25]
14 U U U U U [34]
15 U U U [4]
16 U U [39]
17 U U U U U U [5]
18 U U U U U SRY only U [9]
19 U U U [6]
20 U U [37]
21 U U U U [23]
22 U U U U U U [7]
23 U U U U [29]
24 U U U U U U [8]
25 U U U U U [38]
26 U U U U U U [24]
27 U U U U U U [2]
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reproducibility (No. 13) was not covered at all. On the other hand,
materials and methods (No. 8) were well described. The reference
standard (No. 7) was mentioned in all but two studies but rarely
described comprehensively. Numbers and training of test readers
(No. 10) were rarely reported, and cut-off or category of result (No.
9) was not covered in any of the studies.
When reporting results, the actual date of the study was rarely
recorded (No. 14). Details of the study population generally only
included information on the gestational age of the fetus but not the
characteristics of women (No. 15). The proportion of participants
satisfying criteria for inclusion was also rarely reported (No. 16).
Reporting of test results was often vague with limited details of
diagnostic test parameters or measures of statistical certainty (No.
21), while estimates of variability between different patient
populations, test readers or centres together with estimates of
test reproducibility (Nos. 23 and 24) were not reported in any
study. Handling of missing responses and indeterminate results
(No. 22) was reported in two-thirds of papers. Adverse events were
not reported (No. 20) although the relevance of this item might be
questioned, asmight that relating to the severity of disease in those
tested (No. 18). The time interval between index test and reference
standard could only be estimated from the type of reference
standard used, i.e. postnatal serology, amniocentesis or CVS (No.
17). A cross tabulation of results was presented in nearly all studies
(No. 19). Finally, discussion of the clinical applicability of the study
ﬁndings was covered in all studies (No. 25).
A detailed comparison of STARD checklist scores across papers
would appear to indicate that articles have consistent weaknesses
in their reporting, and published studiesmay, therefore, not be free
from bias, with some indication that reported diagnostic accuracy
rates may be overestimates. In terms of their applicability to thePlease cite this article in press as: Freeman K, et al. Non-invasive fe
reporting of diagnostic accuracy in published studies. Eur J Obstet Gservice setting, certain STARD items could havemajor implications
for clinical implementation of NIPD testing for fetal RHD
genotyping, while others might not apply directly to the NIPD
test being evaluated. For instance, a description of cut-offs and
categories (STARD list item No. 9) is not obviously applicable to
RhD NIPD. Any differential implication that speciﬁc items might
have for clinical application of RhDNIPD is not reﬂected in the ﬁnal
score since all STARD items carry equal weight. The STARD score,
therefore, should not be interpreted as a stand-alone measure of
the quality of studies of RhD NIPD diagnostic accuracy. There may
be speciﬁc questions and unique characterisations which are
important for this type of genetic diagnostic tool.
3.2. Assessment against NIPD proforma
An in-house proforma translated the list of general short-
comings identiﬁed by STARD into areas of weakness speciﬁcally
relevant to RhD NIPD accuracy. Four main areas, previously
reported by the STARD group [22], incorporating eight speciﬁc
aspects, were identiﬁed as most likely to compromise the internal
as well as external validity of NIPD studies (Table 2). A lack of
discussion of ﬂaws in these areas might lead to inappropriate
decisions on adoption of the test.
3.3. Study population
Table 2 clearly indicates that a number of researchers
concentrated on samples from at risk pregnancies (e.g. Down
syndrome), including women who may not resemble the general
RhD-negative pregnant population [5,8,9,15,23–26]. Since recruit-
ment was carried out selectively, test accuracy reported in such
studies might be an overestimate because certain fetal conditionstal RHD genotyping tests: A systematic review of the quality of
ynecol (2008), doi:10.1016/j.ejogrb.2008.10.010
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the maternal circulation [27], consequently increasing the
sensitivity of the test. Only 5 studies made reference to the
sensitisation status of the sample population [6,15,16,28,29]. Poor
characterisation of the sample population or selective sampling
might affect the reliability of reported results equally. Selective
sampling was taken even further in two studies that only recruited
RhD-negative pregnant women with RhD-positive fetuses [15,29].
Both studies excluded any possibility of producing false positives
and did not sufﬁciently challenge the test because a certain test
outcome was anticipated. This is also true for one study that
included samples from four women with weak D phenotypes
[30]. Fetuses of women with such a phenotype cannot currently
be tested non-invasively. While identiﬁcation of such individuals
is an important feature of the test in order to avoid false
positives, knowledge of inclusion of such samples, again, implies
an anticipation of identifying these four women. Restriction of
samples to Caucasians also reduced the validity of ﬁndings, as did
failure to report the ethnic make-up of the study population (20
studies). This is particularly relevant for RHD genotyping because
of the genetic variation observed in different ethnic groups. Only
four studies speciﬁcally identiﬁed their study populations as of
mixed ethnicity [13,25,31,32].
3.4. Study conduct and data analysis
A third aspect concerns the handling of data on replicate
samples. Twenty studies reported the number of replicates used,
which ranged from two to seven for fetal DNA samples and up to 11
when using fetal cells. Out of these, ﬁve studies used a different
number of replicates for different samples [9,14,30,33,34] and four
studies presented no, or insufﬁcient, information on how replicates
were handled. Seven studies either did not include replicates or did
not report them. Protocols for conversion of replicate outcomes
into an overall test result differed signiﬁcantly across the studies,
ranging from a requirement for one or more positive replicate
outcome [2,13,28,29,30,32–34] to two or more [6,16,25,35] or all
replicates [14,15,31,35,36] to be positive for an overall positive
result.
A fourth aspect relates to reporting of test failure rates and
whether the reported accuracy is adjusted for the number of
retests. A test failure rate, which is derived from the number
of excluded samples due to inconclusive results, lack of material
or maternal variant genes, was reported in only 12 studies
[4–6,13–16,25,29–31,35]. Out of these, only one group of authors
considered the failure rate in their analysis of test accuracy [31]
and one mentioned the revised overall success rate only in their
comments [15]. In all studies that provided data on their test
failure rate, inclusion of these samples would result in a lower
accuracy [13–16,25,29–31,35]. This was also demonstrated in a
recent meta-analysis [20].
3.5. Study design
A ﬁnal two aspects concern the controls included in a study.
Ideally, for RhD NIPD these should include (a) controls of known
RhD genotypes and (b) controls for the presence of fetal material.
Use of control samples of known RhD type (positive as well as
negative) and run at the same time as the index test was reported
in only 10 studies [4,5,13,15,25,29,32,37–39]. Only two of these
were controls frompregnantwomenwith knownRhD-positive or -
negative fetuses. The other studies used control samples from
males, non-pregnant females or combinations of both. Controls
of known RhD variants that some studies claimed to be able to
distinguish were not reported in those papers.Please cite this article in press as: Freeman K, et al. Non-invasive fe
reporting of diagnostic accuracy in published studies. Eur J Obstet GUse of a control for the presence of fetal DNA was reported in
only seven studies [9,13,14,16,31,32,36]. There was no consistency
in the type of control used. Y-linked markers were used in two
studies but these are unable to provide a positive control for female
fetuses [9,34]. Insertion deletion polymorphisms (IDPs) were used
in four studies; these are sex independent and appear reasonably
robust [14,16,31,36]. However, using 11 [14] and 8 [31] IDPs, the
authors report that the presence of fetal DNA could not be
conﬁrmed in a small number of samples. Spiking samples with
mouse DNA was not sufﬁcient as a control for the presence of DNA
[5], since a true control requires DNA of fetal origin. Employment of
RHCE as a control for fetal DNA in a further study was not sufﬁcient
because of the maternal genetic background [13].
4. Discussion
Articles which report the diagnostic accuracy of new non-
invasive prenatal diagnostic tests for RHD genotyping are difﬁcult
to identify through systematic searches of the literature. Indexing
of the articles identiﬁedwas found to be poor, as has been reported
by other diagnostic test reviews [40]. Of those ﬁnally identiﬁed,
less than one-third were found to have included the correct MeSH
headings for diagnostic accuracy.
A detailed appraisal of all retrieved articles has identiﬁed a
generally poor quality of reporting when papers are scored against
international standards for studies reporting diagnostic accuracy
and against an in-house NIPD proforma. The weaknesses identiﬁed
are similar to those mentioned in two recent papers [41,42]. The
shortcomings observed will be signiﬁcant if they cause the ﬁnal
test accuracy, after adjustment, to fall below a level that is
acceptable in the context of their proposed clinical use [41].
A recent publication reviewing the current stage of RhD NIPD
test development reported a test diagnostic accuracy of>99% [43].
At the same time, a meta-analysis of published studies has
reported an accuracy of 94.8% [20]. While an accuracy of >99%
might be sufﬁciently high for a diagnostic test in clinical practice,
an accuracy rate of 94% has been identiﬁed as suboptimal for
clinical practice [41]. Further in their meta-analysis Geifman-
Holtzman et al. [20] report an overall accuracy rate of only 91.4%
when considering all samples, including those that had been
excluded by study authors. Our review indicates widespread
exclusion of inconclusive results, and of samples with insufﬁcient
fetal material or those with maternal variant genes, which will
both have important implications for population wide implemen-
tation. This is apparent when one considers that in clinical practice
all such samples excluded from an analysis would represent
individuals for whom the test cannot produce a result. Although
the two main factors that will limit broad-scale application of RhD
NIPD are false negatives and false positives, it is, therefore,
important to also achieve a reduction in the number of excluded
samples.
False negatives may be due to lack of fetal material as well as
suboptimal test sensitivity. However, an internal control to
routinely conﬁrm the presence of fetal DNA in the sample is not
yet available [13]. Sex independent controls such as IDPs cannot be
used as internal controls and highly polymorphic short tandem
repeats (STRs), although discussed as a potential control, are
reported to exhibit much lower sensitivity than the sensitivity for
RHD genotyping [25]. Lack of a suitable control is currently amajor
limitation of the test for clinical practice.
Our review also identiﬁed particular study weaknesses in
patient sampling. Selective participant sampling can result in a
study population that does not resemble the general population to
be tested in clinical practice. Similarly, a lack of consistency in the
handling and reporting of replicates will limit the generalisabilitytal RHD genotyping tests: A systematic review of the quality of
ynecol (2008), doi:10.1016/j.ejogrb.2008.10.010
Fig. 2. Recommendations for the reporting of genetic diagnostic test accuracy for RhD NIPD.
K. Freeman et al. / European Journal of Obstetrics & Gynecology and Reproductive Biology xxx (2008) xxx–xxx 7
G Model
EURO-6442; No of Pages 8of study ﬁndings. Randen et al. [34] reported a decrease in the
number of false results and an increase in accuracy when only one
positive result, rather than all replicate outcomes, were consid-
ered. Reported test performance is, therefore, laboratory speciﬁc
and might not be replicated in routine clinical practice.
All the articles identiﬁed in this review are based on data from a
single laboratory, with tests undertaken under varying protocols,
and results mostly derived from small sample numbers. The
establishment of large-scale, standardised RhD NIPD test protocols
is a key objective of the Special Non-invasive Advances in Fetal and
Neonatal Evaluation (SAFE) Network established by the European
Commission (www.safenoe.org).
To date, a major weakness in terms of the emerging evidence
base of RhD NIPD has been the lack of any objective discussion
regarding these various ﬂaws and their consequences for
implementation in clinical practice. Furthermore, due to the lack
of peer-reviewed studies reporting on high-throughput testing of
non-sensitised women, discussion of the implementation of this
test application is based on results from small-scale studies. Since
it implies testing a much larger number of women, the evidence
base from small-scale studies should not be taken forward to large-
scale testing of non-sensitised women. For instance, the number ofPlease cite this article in press as: Freeman K, et al. Non-invasive fe
reporting of diagnostic accuracy in published studies. Eur J Obstet Gretests will determine the cost of the test, as well as its reliability.
No articles address the issue of cost versus quality. Although our
review has concentrated on the quality of studies in terms of their
reporting of diagnostic accuracy, and not on scientiﬁc aspects such
as the primers employed, the latter are also important. Scientiﬁc
aspectswill inevitably affect the ultimate accuracy of the test in the
wider population since they determinewhich of themany variants
would be detected or missed.
In conclusion, based on our ﬁndings we would recommend that
following standardisation to identify best practice for methodol-
ogy and materials for RhD NIPD, consensus should also be reached
on the required number and handling of replicates, since test
accuracy was observed to be repeatedly improved in papers by
discounting dissimilar replicates [14,30,33] or sample test out-
comes [2,6,14,30,35,37].
Furthermore, when carrying out meta-analyses, methods to
take account of the quality of studies as well as their sample size
should be considered since disregard of the quality of NIPD study
design may lead to erroneous conclusions about test accuracy.
High-quality trials evaluating the diagnostic accuracy of RhD NIPD
tests are urgently needed. Examination of articles published to
February 2008 identiﬁes a continued absence of large-scale, peer-tal RHD genotyping tests: A systematic review of the quality of
ynecol (2008), doi:10.1016/j.ejogrb.2008.10.010
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EURO-6442; No of Pages 8reviewed trials. We would recommend that such studies adhere to
the STARD checklist and the recommendations (Fig. 2) speciﬁc for
NIPD, and that these are consulted at the planning stage of all
future NIPD studies.
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